These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31819196)

  • 1. Defining a metabolic landscape of tumours: genome meets metabolism.
    Seth Nanda C; Venkateswaran SV; Patani N; Yuneva M
    Br J Cancer; 2020 Jan; 122(2):136-149. PubMed ID: 31819196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.
    Ge T; Gu X; Jia R; Ge S; Chai P; Zhuang A; Fan X
    Cancer Commun (Lond); 2022 Nov; 42(11):1049-1082. PubMed ID: 36266736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.
    Chang WH; Lai AG
    BMC Cancer; 2020 Aug; 20(1):773. PubMed ID: 32807122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing gone awry: distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies.
    Chang WH; Lai AG
    J Transl Med; 2019 Apr; 17(1):132. PubMed ID: 31014368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated metabolism contributes to oncogenesis.
    Hirschey MD; DeBerardinis RJ; Diehl AME; Drew JE; Frezza C; Green MF; Jones LW; Ko YH; Le A; Lea MA; Locasale JW; Longo VD; Lyssiotis CA; McDonnell E; Mehrmohamadi M; Michelotti G; Muralidhar V; Murphy MP; Pedersen PL; Poore B; Raffaghello L; Rathmell JC; Sivanand S; Vander Heiden MG; Wellen KE;
    Semin Cancer Biol; 2015 Dec; 35 Suppl():S129-S150. PubMed ID: 26454069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis.
    Min BH; Hwang J; Kim NK; Park G; Kang SY; Ahn S; Ahn S; Ha SY; Lee YK; Kushima R; Van Vrancken M; Kim MJ; Park C; Park HY; Chae J; Jang SS; Kim SJ; Kim YH; Kim JI; Kim KM
    J Pathol; 2016 Nov; 240(3):304-314. PubMed ID: 27514024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer.
    Tan YT; Lin JF; Li T; Li JJ; Xu RH; Ju HQ
    Cancer Commun (Lond); 2021 Feb; 41(2):109-120. PubMed ID: 33119215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational landscape of RNA-binding proteins in human cancers.
    Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
    RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Flexibility Is a Determinant of Breast Cancer Heterogeneity and Progression.
    Fukano M; Park M; Deblois G
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.
    Zhu Y; Li X; Wang L; Hong X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():988295. PubMed ID: 36046791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations.
    Choi H; Na KJ
    Mol Cancer; 2018 Oct; 17(1):150. PubMed ID: 30333042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
    Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
    J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases.
    Zhang Y; Meng Q; Sun Q; Xu ZX; Zhou H; Wang Y
    Mol Metab; 2021 Feb; 44():101131. PubMed ID: 33278637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shining a light on metabolic vulnerabilities in non-small cell lung cancer.
    Dowling CM; Zhang H; Chonghaile TN; Wong KK
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188462. PubMed ID: 33130228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
    Kumar Mamidi TK; Wu J; Hicks C
    Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Untangling a complex web: Computational analyses of tumor molecular profiles to decode driver mechanisms.
    Khalighi S; Singh S; Varadan V
    J Genet Genomics; 2020 Oct; 47(10):595-609. PubMed ID: 33423960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium Channels in Cancer.
    Ganser K; Klumpp L; Bischof H; Lukowski R; Eckert F; Huber SM
    Handb Exp Pharmacol; 2021; 267():253-275. PubMed ID: 33864122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Co-Expression Analyses Allow the Identification of Critical Signalling Pathways Altered during Tumour Transformation and Progression.
    Savino A; Provero P; Poli V
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-specific tumorigenesis: context matters.
    Schneider G; Schmidt-Supprian M; Rad R; Saur D
    Nat Rev Cancer; 2017 Apr; 17(4):239-253. PubMed ID: 28256574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unravelling the tumour genome: The evolutionary and clinical impacts of structural variants in tumourigenesis.
    Hamdan A; Ewing A
    J Pathol; 2022 Jul; 257(4):479-493. PubMed ID: 35355264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.